Role of serotonin in angiogenesis: Induction of angiogenesis by sarpogrelate via endothelial 5-HT1B/Akt/eNOS pathway in diabetic mice

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 337-342

  Iwabayashi, Masaaki ^a   Taniyama, Yoshiaki ^a   Sanada, Fumihiro ^a   Azuma, Junya ^a   Iekushi, Kazuma ^a   Kusunoki, Hiroshi ^a   Chatterjee, Amarnath ^a   Okayama, Keita ^a   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT1B; Diabetes mellitus; ENOS; Sarpogrelate; Serotonin

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SARPOGRELATE; SEROTONIN; SEROTONIN 1B RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; LEG BLOOD FLOW; LEG ISCHEMIA; LIMB PERFUSION; MOUSE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASODILATATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HINDLIMB; HUMANS; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT2A; REGIONAL BLOOD FLOW; SEROTONIN; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION; SUCCINATES; TIME FACTORS; VASODILATION;

EID: 84855941554     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.042     Document Type: Article

References (27)

1. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease: the Framingham study. Journal of the American Medical Association 1979, 241:2035.
2. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003, 348:383.
3. Second European Consensus Document on chronic critical leg ischemia. Circulation 1991, 84:IV1-IV26.
4. Barradas M., Gill D., Fonseca V., Mikhailidis D., Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. European Journal of Clinical Investigation 1988, 18:399-404.
5. Malyszko J., Urano T., Knofler R., et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thrombosis Research 1994, 75:569-576.
6. Hara K., Hirowatari Y., Yoshika M., Komiyama Y., Tsuka Y., Takahashi H. The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. Journal of Laboratory and Clinical Medicine 2004, 144:31-37.
7. Pakala R., Willerson J.T., Benedict C.R. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997, 96:2280.
8. Lee S., Wang W., Moore B., Fanburg B. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circulation Research 1991, 68:1362.
9. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cellular and Molecular Life Sciences 2005, 62:159-170.
10. Tanaka N. Pharmacological studies on responsiveness of 5-hydroxytryptamine in overcoming perioperative spasm of coronary artery bypass graft. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan 2009, 129:1049.
11. Hara H., Osakabe M., Kitajima A., Tamao Y., Kikumoto R. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thrombosis and Haemostasis 1991, 65:415.
12. Miyazaki M., Higashi Y., Goto C., et al. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. Journal of Cardiovascular Pharmacology 2007, 49:221.
13. Nishihira K., Yamashita A., Tanaka N., et al. Inhibition of 5-hydroxytryptamine2A receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. Journal of Thrombosis and Haemostasis 2006, 4:247-255.
14. Bir S., Fujita M., Marui A., et al. New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia. Circulation Journal: Official Journal of the Japanese Circulation Society 2008, 72:633.
15. Li T., Furutani A., Takahashi M., et al. Impaired potency of bone marrow mononuclear cells for inducing therapeutic angiogenesis in obese diabetic rats. American Journal of Physiology - Heart and Circulatory Physiology 2006, 290:H1362.
16. Hoyer D., Clarke D., Fozard J., et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacological Reviews 1994, 46:157.
17. Fujita M., Minamino T., Sanada S., et al. Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. Journal of Molecular and Cellular Cardiology 2004, 37:1219.
18. Iekushi K., Taniyama Y., Azuma J., et al. Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin. Hypertension 2007, 49:1409.
19. Murohara T., Asahara T., Silver M., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. Journal of Clinical Investigation 1998, 101:2567.
20. Mcduffie J.E., Coaxum S.D., Maleque M.A. 5-Hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures. Proceedings of the Society for Experimental Biology and Medicine 1999, 221:386-390.
21. Park K., Chung W.Y., Seo J.B., et al. The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial. Trial 2010, 11:122.
22. Morishita R., Makino H., Aoki M., et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:713-720.
23. Lawall H., Bramlage P., Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. Thrombosis and Haemostasis 2010, 103:696-709.
24. Yang M., Li K., Ng P.C., et al. Promoting effects of serotonin on hematopoiesis: ex vivo expansion of cord blood CD34+ stem/progenitor cells, proliferation of bone marrow stromal cells, and antiapoptosis. Stem Cells 2007, 25:1800-1806.
25. Ohkura M., Tanaka N., Kobayashi H., Wada A., Nakai J., Yamamoto R. Insulin induces internalization of the 5-HT2A receptor expressed in HEK293 cells. European Journal of Pharmacology 2005, 518:18-21.
26. Kahn A.M., Allen J.C., Seidel C.L., Song T. Insulin inhibits serotonin-induced Ca2+ influx in vascular smooth muscle. Circulation 1994, 90:384.
27. Ho F., Lin W., Chen B., et al. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-[kappa] B and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cellular Signalling 2006, 18:391-399.